## **CCSS Application of Intent Submission**

Name: Zhaoming Wang Institution: St Jude Children's Research Hospital Address: Street Address: 262 Danny Thomas Place City: Memphis State: TN Zip Code: 38105 Country: United States

Email Address: <a href="mailto:zhaoming.wang@stjude.org">zhaoming.wang@stjude.org</a> Phone Number: 9015950232 Alternate Phone Number: 9014267840

**Project Requirements and Description** 

Requirements to submit AOI:

	Yes	No
A comprehensive review of previously published data has been completed	<	-
The specific aims are clear and focused	<	-
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.	<	-
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months	⊻	-

## **Project Title:**

Epigenetic Approach in Understanding the Risk of Cardiometabolic Conditions

#### Planned research population:

2,885 survivors with pre-existing WGS/WES and new DNA methylation profiling data to be generated with stored blood samples.

### **Proposed specific aims:**

Aim 1: Evaluate epigenetic factors (specifically, DNA methylation) as mediators of the association between cancer treatment exposures or health behaviors and risk of cardiometabolic conditions.

Aim 2: Evaluate epigenetic age as an independent predictor of cardiometabolic risk, while adjusting for genetic and epigenetic factors.

Will the project require non-CCSS funding to complete?: Yes If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: NIH R01 Does this project require contact of CCSS study subjects for:

	Yes	No
Additional self-reported information		×
Biological samples	-	×
Medical record data		⊻

If yes to any of the above, please briefly describe:

Cardiometabolic conditions including five modifiable CVD risk increasing conditions (abnormal glucose metabolism, obesity, hypertension, hypertriglyceridemia, and hypercholesterolemia) and two end-organ cardiac damage (cardiomyopathy and myocardial infarction).

# What CCSS Working Group(s) would likely be involved?:

	Primary	Secondary
Second Malignancy	-	-
Chronic Disease	-	×
Psychology/Neuropsychology	-	-
Genetics	×	-
Cancer Control	-	-
Epidemiology/Biostatistics	-	-

### **Outcomes or Correlative Factors**

Late Mortality and Second Malignancy: Not selected

Health Behaviors:

	Primary	Secondary	Correlative Factors
Торассо	-	-	⊻
Alcohol	-	-	⊻
Physical Activity	-	-	. ✓
Medical Screening	-	-	. ✓
Other	-	-	-

If other, please specify:

Psychosocial: Not selected

If other, please specify:

## Medical Conditions:

	Primary	Secondary	Correlative Factors
Hearing/Vision/Speech	-	-	-
Hormonal Systems	-	-	-
Heart and Vascular	✓	-	-
Respiratory	-	-	-
Digestive	-	-	-
Surgical Procedures	-	-	-
Brain and Nervous System	-	-	-
Other	-	-	-

If other, please specify:

Medications Describe medications:

Psychologic/Quality of Life: Not selected

If other, please specify:

Other:

# Demographic:

	Primary	Secondary	Correlative Factors
Age	-	-	⊻
Race	-	-	⊻
Sex	-	-	✓
Other	-	-	-

If other, please specify:

Cancer Treatment:

	Correlative Factors
Chemotherapy	✓
Radiation Therapy	✓
Surgery	-

## **Anticipated Sources of Statistical Support:**

	Yes	No
CCSS Statistical Center	×	-
Local Institutional Statistician	×	-

If local, please provide the name(s) and contact information of the statistician(s) to be involved: Qian Dong, PhD email: <u>Qian.Dong@stjude.org</u> Will this project utilize CCSS biologic samples?: Yes If yes, which of the following?: If other, please explain:

## **Other General Comments**

General comments: I discussed with Dr. Armstrong about adding this set of CCSS data (new, pending on the CCSS Supplement funds) for replication in my R01 grant application where ~4000 survivors in SJLIFE with genetic/epigenetic data will be used for discovery to study the mechanisms of increased risk of treatment- and health behavior related cardiometabolic conditions among survivors of childhood cancer.